


\begin{enumerate}
	\item INNOVATION, IMITATION and Market Structure in Pharmaceuticals \cite{key400}
	\item Strategies drug DISCOVERY from random GENERATED libraries to rational DESIGN \cite{key500}
	\item Movement from large MAXIMUM DIVERSE libraries to SMALL “drug-like” libraries. \cite{key500}
\end{enumerate}

\section{Pharmaceutical Immuno-Oncology Portfolio Object}

\begin{table}
	\caption{Mono-Clonal Anti-Bodies for the Immuno-Oncology Portfolio \cite{key8001} }
	\begin{tabular}{r|p{4cm}|l}
		Compound & Company & Comment \\
		\hline
		Revlimid & Celgene & \\
		Opdivo & Bristol-Myers Squibb Ono Pharmaceutical & \\
		Imbruvica & AbbVie (Pharmacyclics) Johnson and Johnson & \\
		Keytruda & Merck and Company & \\
		Ibrance & Pfizer & \\
		Tecentriq & Roche & \\
		Darzalex & Johnson and Johnson & \\
		Perjeta & Roche & \\
		Xtandi & Astellas Pharma and Pfizer & \\
		Avastin & Roche & \\
		Herceptin & Roche & \\
		Gazyva & Roche & \\
		Jakafi & Novartis & \\
		Venclexta & Roche & \\
		Rituxan & Roche, Pharmstandard & \\
		\hline
	\end{tabular}
\end{table}


\section{References}


\subsection{Combinatorial Chemistry}

\bibitem[1]{key500}Richard Pommier Swanson (2004)
\newblock The Entrance of Informatics into Combinatorial Chemistry
\newblock American Society for Information Science and Technology


\subsection{Immuno-Oncology}

\bibitem[2]{key8001}Special Report (2017)
\newblock Top 15 Best Selling Cancer Drugs 2022
\newblock Retrieved July 31, 2018, from https://www.fiercepharma.com/special-report/special-report-top-15-best-selling-cancer-drugs-2022

\subsection{Econometrics}

\bibitem[3]{key400} Christian Garavaglia, Franco Malerba, Luigi Orsenigo, Michele Pezzoni (2014)
\newblock Innovation and Market Structure in Pharmaceuticals An Econometric Analysis on Simulated Data
\newblock Jahrbücher für Nationalökonomie und Statistik 
